Project Grant R01CA308771
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $649K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Albany, NY 12208, USA
Similar Awards
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2028. The award supports fundamental research to decipher mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugate therapy, specifically examining the drug sacituzumab govitecan (SG), which is approved for...
- Federal Grant Award Summary New York University School of Medicine received a $585,482 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 31, 2031. This five-year research award supports fundamental investigations into the molecular mechanisms of breast cancer metastasis, specifically examining the dual role of the translation factor DAP5 (Death-Associated Protein 5) in selective messenger RNA...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded Matrisome Bio, Inc. a $2.47M Project Grant on September 23, 2025, to develop an extracellular matrix (ECM)-targeted theranostic radiopharmaceutical for metastatic lung cancer. The grant, which runs through August 31, 2027, supports the development of nanobody-based molecularly targeted therapeutics that selectively bind to disease-associated ECM proteins highly expressed in lung...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $1.056 million to the Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) to support research on overcoming resistance to targeted therapies in breast cancer. Initiated August 20, 2025, and extending through July 31, 2032, this project delivers fundamental and applied research aimed at understanding and addressing the development of drug resistance in...
- Federal Grant Award Summary This project grant from the National Cancer Institute (NCI), awarded under the Cancer Biology Research program (CFDA 93.396), provides $1.31M in funding to Weill Medical College of Cornell University to conduct fundamental research on signal transduction mechanisms related to p70 S6 kinase 1 (S6K1) and mammalian target of rapamycin complex 1 (mTORC1) signaling in cancer cells. The award, granted July 10, 2025, with a completion date of April 30, 2030, supports a...
- Federal Project Grant Award Summary Harvard College received a $604,102 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on May 1, 2026, for completion by April 30, 2031. This award funds the development of bioprinted three-dimensional (3D) vascular cancer models designed to advance understanding of T cell immunotherapy in solid tumors. The research will deliver both murine and human cancer models using microporous...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $430,521 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on March 13, 2026, with completion expected by February 28, 2029. The award funds the development and validation of novel monoclonal antibody tools designed to explore altered glycosylation patterns in tumor cells. The research will generate tumor-associated carbohydrate antigen (TACA)-specific...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...